Teva Pharmaceutical Industries Ltd.

Major Shareholding Notification • Aug 6, 2025

FORM 44			OMB APPROVAL
Check this box if no longer subject to Section 1166 Form 44 or Form 55 obligations may continue See Instruction 11((b)) Check this box to indicate that a transaction was made pursuant to a contract,, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 1100b55--11((c)) See Instruction 1100 ((Print or Type Responses))		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,, DC 2200554499 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 1166((a)) of the Securities Exchange Act of 11993344 or Section 3300((h)) of the Investment Company Act of 11994400	OMB Number:: Estimated average burden hours per response	33223355--00228877 0055
11 Name and Address of Reporting Person ** Hughes Eric A		22 Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	55 Relationship of Reporting Person((s)) to Issuer ((Check all applicable))	_____ 1100%% Owner
((Last)) ((First)) C//O Teva Pharmaceutical Industries Ltd 112244 Dvora HaNevi''a St,,	((Middle))	33 Date of Earliest Transaction ((Month//Day//Year)) 0088//0011//22002255	_ Director X __ Officer ((give title below)) _____ Other ((specify below)) See ""Remarks""
((Street))		44 If Amendment,, Date Original Filed ((Month//Day//Year))	66 Individual or Joint//Group Filing ((Check Applicable Line)) _ X _ Form filed by One Reporting Person
Tel Aviv,, L33 66994444002200			___ Form filed by More than One Reporting Person

Table I -- Non--Derivative Securities Acquired,, Disposed of,, or Beneficially Owned 22.. Transaction Date ((Month //Day//Year)) 22A.. Deemed Execution Date,, if any 33.. Transaction Code ((Instr.. 88)) 44.. Securities Acquired ((A)) or Disposed of ((D)) ((Instr.. 33,, 44 and 55)) 55.. Amount of Securities Beneficially Owned Following Reported Transaction((s)) ((Instr.. 33 and 44))

((City)) ((State)) ((Zip))

11Title of Security ((Instr 33))	22 Transaction Date ((Month //Day//Year))	22A Deemed Execution Date,, if any ((Month//Day //Year))	33 Transaction Code ((Instr 88))		44 Securities Acquired ((A)) or Disposed of ((D)) ((Instr 33,, 44 and 55))			55 Amount of Securities Beneficially Owned Following Reported Transaction((s)) ((Instr 33 and 44))	66 Ownership Form::	77 Nature of Indirect Beneficial
			Code	V	Amount	((A)) or ((D))	Price		Direct ((D)) or Indirect ((I)) ((Instr 44))	Ownership ((Instr 44))
Ordinary Shares ((11))	0088//0011//22002255		M		5522,,774422	A	((22))	5522,,774422	D
Ordinary Shares ((11))	0088//0011//22002255		((33)) S		5522,,774422	D	\$\$ 115511557755 ((44))	00	D

Table II -- Derivative Securities Acquired,, Disposed of,, or Beneficially Owned
(( eg ,, puts,, calls,, warrants,, options,, convertible securities))

11 Title of Derivative Security ((Instr 33))	22 Conversion or Exercise Price of Derivative Security	33 Transaction 33A Deemed 44 Transaction Date ((Month Execution Code //Day//Year)) Date,, if any ((Instr 88)) ((Month//Day //Year))			55 Number of Derivative Securities Acquired ((A)) or Disposed of ((D)) ((Instr 33,, 44,, and 55))		66 Date Exercisable and Expiration Date ((Month//Day//Year))		77 Title and Amount of Underlying Securities ((Instr 33 and 44))		88 Price of Derivative Security ((Instr 55))	99 Number of Derivative Securities Beneficially	1100 Ownership Form of Derivative Security::	1111 Nature of Indirect Beneficial Ownership ((Instr 44))
				Code	V	((A))	((D))	Date Exercisable Expiration Date		Title	Amount or Number of Shares		Owned Following Reported ((I)) Transaction ((s)) ((Instr 44))	Direct ((D)) or Indirect ((Instr 44))
Restricted Share Units	((22))	0088//0011//22002255		M			5522,,774422	((55))	((55))	Ordinary Shares ((11))	5522,,774422	\$\$ 00	5522,,774444	D

Explanation of Responses::

11.. The Ordinary Shares may be represented by American Depositary Shares,, each of which currently represents one Ordinary Share..

22.. Each restricted share unit represents a contingent right to receive,, at settlement,, one ordinary share or,, at the option of the Human Resources and Compensation Committee,, the cash value of one ordinary share..

33.. The transaction reported in this Form 44 was effected pursuant to a Rule 1100b55--11 trading plan adopted by the reporting person on November 1155,, 22002244..

• 44.. The price reported in Column 44 is a weighted average price.. These shares were sold in multiple transactions at prices ranging from \$\$1155..1133 to \$\$1155..3311,, inclusive.. The reporting person undertakes to provide,, upon request by the SEC staff,, the issuer,, or any security holder of the issuer,, full information regarding the number of shares sold at each separate price..
• 55.. Restricted share units were granted on August 11,, 22002222,, with 5522,,774422 vested on each of August 11,, 22002233,, August 11,, 22002244 and August 11,, 22002255,, and 5522,,774444 vesting on August 11,, 22002266..

Remarks::

Executive Vice President,, Global R&&D and Chief Medical Officer

//s// Dov Bergwerk as attorney--in--fact for Eric A.. Hughes 0088//0055//22002255

Signature of Reporting Person **** Date

Reminder:: Report on a separate line for each class of securities beneficially owned directly or indirectly..

** If the form is filed by more than one reporting person,, see Instruction 44((b))((v))..

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.. See 1188 U..S..C.. 11000011 and 1155 U..S..C.. 7788ff((a))..

Note:: File three copies of this Form,, one of which must be manually signed.. If space is insufficient,, see Instruction 66 for procedure..

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number..